secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001171843-22-005457
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q2 net loss $0.77/sh; barzolvolimab Ph2 studies initiated; settles SRS litigation
--------------------------------------------------------------------------------

- Net loss $36M ($0.77/sh) vs $13.4M ($0.34/sh) in Q2 2021; revenue $0.2M down from $3.5M.
- Cash $356.8M at June 30; management says sufficient through 2025.
- Barzolvolimab interim CSU: mean UAS7 reduction 66.6% (1.5mg/kg) and 75.1% (3mg/kg); Phase 2 studies dosed.
- Settled Kolltan contingent milestones reduced from $172.5M to $80M; $15M paid in July; $6.3M remeasurement gain.
- Deprioritized CDX-1140 program; focusing on barzolvolimab and bispecific platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184322005457/0001171843-22-005457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184322005457/f8k_080822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer